A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study in Patients With Coronary Heart Disease (CHD) to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of APL180.

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multiple Dose Study in Patients With Coronary Heart Disease (CHD) to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Subcutaneous Administration of APL180.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Dec 2009

At a glance

  • Drugs APL 180 (Primary)
  • Indications Coronary artery disease
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 21 Nov 2009 Status changed from not yet recruiting to completed as reported by ClinicalTrials.gov.
    • 21 Nov 2009 Actual patient number (104) added as reported by ClinicalTrials.gov.
    • 27 May 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top